Furthermore, we conducted TCR and B‐cell receptor (BCR) repertoire sequencing during the ISAC‐TFR study approved by the Institutional Review Board of Saga University (protocol No. 2021‐05‐02; T‐cell Immunity and Tumor‐Specific Antigens Contribute to Treatment‐Free Remission following tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia) to identify epitope motifs recognized by the TCR to achieve TFR. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.